Compare FR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | KRYS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.6B |
| IPO Year | 1996 | 2017 |
| Metric | FR | KRYS |
|---|---|---|
| Price | $58.89 | $327.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $72.25 | ★ $392.11 |
| AVG Volume (30 Days) | ★ 819.0K | 204.3K |
| Earning Date | 10-14-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | 1.66 | ★ 3.62 |
| Revenue | ★ $727,076,000.00 | $389,130,000.00 |
| Revenue This Year | $8.07 | $31.33 |
| Revenue Next Year | $6.68 | $27.55 |
| P/E Ratio | ★ $36.55 | $93.08 |
| Revenue Growth | 8.58 | ★ 33.94 |
| 52 Week Low | $50.29 | $179.16 |
| 52 Week High | $69.88 | $382.54 |
| Indicator | FR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 41.98 |
| Support Level | $58.87 | $331.79 |
| Resistance Level | $60.50 | $371.16 |
| Average True Range (ATR) | 0.88 | 9.85 |
| MACD | -0.15 | -1.37 |
| Stochastic Oscillator | 3.27 | 17.44 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.